Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TREPROSTINIL INJECTION safely and effectively. See full prescribing information for TREPROSTINIL INJECTION. TREPROSTINIL injection, for subcutaneous or intravenous use Initial U.S. Approval: May 2002
Medication labelWhy this: Advisory · dailymed-prescription
Treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1)]. In patients with PAH requiring transition from epoprostenol, Treprostinil injection is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
- generic_name
- treprostinil
- product_names
- Treprostinil
- ndc
- 62332-514, 62332-515, 62332-516, 62332-517, 62332-514-20, 62332-515-20, 62332-516-20, 62332-517-20
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en